blu-5937 clinical trial：Clinical Trials Register
Clinical Trials Register
2023年2月1日—TheprimaryefficacyobjectiveistoassesstheeffectofBLU-5937on24-hourcoughfrequencyinanenrichedpopulationofadultswith ...。其他文章還包含有：「A52」、「AboutBLU」、「EfficacyinSOOTHE」、「ADoseEscalationStudyofBLU」、「https」、「ARandomized,Double-Blind,Placebo」、「SafetyandEfficacyofBLU」、「https」、「Phase2StudyofBLU」
查看更多 離開網站
A 52
https://www.templehealth.org
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
About BLU
https://www.sec.gov
The RELIEF trial is a 2-arm dose-escalation, placebo-controlled, and crossover design to assess the efficacy, safety, and tolerability of BLU-5937, a highly ...
Efficacy in SOOTHE
https://erj.ersjournals.com
Here we characterize the TDAEs and impact on efficacy in SOOTHE, a phase 2b trial of the selective P2X3 antagonist BLU-5937 in the treatment of RCC.
A Dose Escalation Study of BLU
https://www.mayo.edu
The purpose of this study is to demonstrate the effectiveness and safety of multiple doses of BLU-5937 in adults suffering from RCC.
https
https://classic.clinicaltrials
沒有這個頁面的資訊。
A Randomized, Double-Blind, Placebo
https://www.ncbi.nlm.nih.gov
To determine the optimal dose of sivopixant, a highly selective P2X3 receptor antagonist, for refractory or unexplained chronic cough (RCC/UCC).
Safety and Efficacy of BLU
https://www.atsjournals.org
Here we report results of a phase 2b study in RCC to assess the safety, efficacy, and optimal doses of BLU-5937, a highly selective. P2X3 ...
https
https://classic.clinicaltrials
沒有這個頁面的資訊。
Phase 2 Study of BLU
https://www.hra.nhs.uk
The new compound BLU-5937 has been shown to block P2X3 receptors sensitised by ATP, which explains why BLU-5937 may be useful in the treatment of chronic cough.